A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medivation, Inc.
• Collaborator: Huntington Study Group

Criteria

Inclusion Criteria:

• Clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD;

• Able to take medication (capsules) by mouth.

Exclusion Criteria:

• Clinical evidence of unstable medical illness;

• Females who are pregnant or lactating or who intend to become pregnant during the study period.